Nazione: Irlanda
Lingua: inglese
Fonte: HPRA (Health Products Regulatory Authority)
ATENOLOL, CHLORTALIDONE
Generics (UK) Limited
C07CB03
ATENOLOL, CHLORTALIDONE
100/25 Milligram
Coated Tablets
Product subject to prescription which may be renewed (B)
Beta blocking agents, selective, and other diuretics
Authorised
1991-05-21
PACKAGE LEAFLET: INFORMATION FOR THE PATIENT ATENETIC 50MG/12.5MG & 100MG/25MG FILM-COATED TABLETS (Atenolol & Chlortalidone) READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS MEDICINE BECAUSE IT CONTAINS IMPORTANT INFORMATION FOR YOU. Keep this leaflet. You may need to read it again. If you have any further questions, ask your doctor or pharmacist. This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours. If you get any side effects talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. See section 4. WHAT IS IN THIS LEAFLET 1. What Atenetic is and what it is used for 2. What you need to know before you take Atenetic 3. How to take Atenetic 4. Possible side effects 5. How to store Atenetic 6. Contents of the pack and other information. 1. WHAT ATENETIC IS AND WHAT IS IT USED FOR Atenetic is used to treat high blood pressure. Atenetic tablets contain a combination of two active medicines, atenolol and chlortalidone. These medicines work together to lower your blood pressure. You have been prescribed this medicine because your blood pressure was not being adequately controlled using atenolol or chlortalidone alone. Atenolol belongs to a class of medicines called selective beta-blockers. It works by making your heart beats more slowly and with less force. Chlortalidone belongs to the class of drugs called diuretics. It works by increasing the amount of urine produced by your kidney. 2. WHAT YOU NEED TO KNOW BEFORE YOU TAKE ATENETIC DO NOT TAKE ATENETIC IF: - you are allergic to atenolol or chlortalidone or any of the other ingredients of this medicine (listed in section 6). - y Leggi il documento completo
SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Atenetic 100 mg/25 mg Film-coated Tablets 2 QUALITATIVE AND QUANTITATIVE COMPOSITION 3 PHARMACEUTICAL FORM Film-coated tablet. White, biconvex, film-coated tablet embossed with 'AC 125' on one side and 'G' on the reverse. 4 CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Atenetic is indicated for the treatment of essential hypertension in patients whose blood pressure is not adequately controlled on atenolol or chlortalidone alone. 4.2 POSOLOGY AND METHOD OF ADMINISTRATION When clinically appropriate direct change from monotherapy to the fixed combination may be considered in patients whose blood pressure is not adequately controlled. Posology ADULTS:- The recommended maintenance dose is one 50mg/12.5mg tablet daily. For patients who do not respond adequately to Atenetic 50mg/12.5mg, the dosage may be increased to one tablet of Atenetic 100mg/25mg Where necessary, another antihypertensive drug, such as a vasodilator, can be added. Patients can be transferred directly to Atenetic 100 mg/25 mg Film-coated Tablets from other hypertensive treatments, with the exception of clonidine (see section 4.5). SPECIAL POPULATIONS: _Use in older people_: Dosage requirements are often lower in this age group. _Paediatric population (children and adolescents <18 years of age)_ The safety and efficacy of atenolol/chlortalidone in children and adolescents less than 18 years have not been established. Therefore, Atenetic is not recommended in children and adolescents. _Use in patients with renal impairment:_ Due to the properties of the chlortalidone component, Atenetic has reduced efficacy in the presence of renal insufficiency. This fixed dose combination should thus not be administrated to patients with severe renal impairment (see section 4.3). Active constituents mg/tablet Atenolol 100 Chlortalidone 25 For full list of excipients, see section 6.1. H E A L T H P R O D U C T S R E G U L A T O R Y A U T H O R I T Y ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ _ Leggi il documento completo